Hunan Jingfeng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
October 29, 2020 at 04:06 am EDT
Share
Hunan Jingfeng Pharmaceutical Co.,Ltd. announced earnings results for the nine months ended September 30, 2020. For the nine months, the company announced sales was CNY 936.497 million compared to CNY 1,033.105 million a year ago. Operating income was CNY 88.776 million compared to operating loss of CNY 143.376 million a year ago. Net income was CNY 75.815 million compared to net loss of CNY 142.943 million a year ago. Basic earnings per share from continuing operations was CNY 0.0862 compared to basic loss per share from continuing operations of CNY 0.1625 a year ago.
Hunan Jingfeng Pharmaceutical Co.,Ltd., formerly Hunan Tianyi Science and Technology Co., Ltd, is a China-based company principally engaged in the research, development, manufacture and sale of chemical drugs, biochemical drugs and traditional Chinese patent drugs. The Company's main products includes cardio and cerebrovascular drugs, antihypertensive and hypolipidemic drugs, orthopedic drugs, anti-tumor products, endocrine drugs, digestive system drugs, antiviral drugs and anti-infective drugs, among others. The Company is also involved in commodity import and export trading, business management and consulting, as well as medical technology consulting business. The Company distributes its products in the domestic market.